Trial Profile
Study of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Primary sclerosing cholangitis; Ulcerative colitis
- Focus Therapeutic Use
- 31 May 2018 New trial record
- 28 May 2018 Results published in the Alimentary Pharmacology and Therapeutics